Bradykinin (BK) and serotonin (5-HT) are vasoactive agents that significantly contribute to the normal functioning of fetoplacental blood flow, including modulation of smooth muscle tone in umbilical vein and arteries. Accordingly, umbilical artery is a crucial component of fetoplacental circulation with the vital function of providing suitable perfusion and nutrition for placenta. The aim of this study was to investigate the effect of potassium channel blockers, namely glibenclamide (an ATP-sensitive K + channel blocker), tetraethylammonium (a non-selective K + channel blocker), Ba 2+ (an inwardly rectifying K + channel blocker) and apamin (a small conductance Ca 2+ -activated K + channel blocker) in BK-and 5-HT-induced actions on isolated human umbilical artery (HUA) in normal pregnancy. The experiments were performed on vascular rings of HUA isolated from umbilical cords that were obtained immediately after vaginal delivery in women with uncomplicated pregnancy. Only the remnant tissue, which would have been otherwise disposed of, has been utilized. Isometric tension of suspended artery rings was continuously recorded. BK (1 nM -1 µM) and 5-HT (1 nM -30 µM) produced concentration-dependent contractions of HUA. Control contractions produced by BK were notably (p < 0.05) enhanced only in the presence of apamin (20 µM), while unaltered by other inhibitors. 5-HT-induced effect was not influenced by any of applied blockers. Our results suggest that small conductance Ca 2+ -activated potassium channels contribute to the fine regulation of maximal BK-induced contraction of HUA in normal pregnancy. On the other hand, potassium channels do not seem to be involved in 5-HTevoked contractile response of umbilical artery.
Bradykinin (BK) and serotonin (5-HT) are vasoactive agents that significantly contribute to the normal functioning of fetoplacental blood flow, including modulation of smooth muscle tone in umbilical vein and arteries. Accordingly, umbilical artery is a crucial component of fetoplacental circulation with the vital function of providing suitable perfusion and nutrition for placenta. The aim of this study was to investigate the effect of potassium channel blockers, namely glibenclamide (an ATP-sensitive K + channel blocker), tetraethylammonium (a non-selective K + channel blocker), Ba 2+ (an inwardly rectifying K + channel blocker) and apamin (a small conductance Ca 2+ -activated K + channel blocker) in BK-and 5-HT-induced actions on isolated human umbilical artery (HUA) in normal pregnancy. The experiments were performed on vascular rings of HUA isolated from umbilical cords that were obtained immediately after vaginal delivery in women with uncomplicated pregnancy. Only the remnant tissue, which would have been otherwise disposed of, has been utilized. Isometric tension of suspended artery rings was continuously recorded. BK (1 nM -1 µM) and 5-HT (1 nM -30 µM) produced concentration-dependent contractions of HUA. Control contractions produced by BK were notably (p < 0.05) enhanced only in the presence of apamin (20 µM), while unaltered by other inhibitors. 5-HT-induced effect was not influenced by any of applied blockers. Our results suggest that small conductance Ca 2+ -activated potassium channels contribute to the fine regulation of maximal BK-induced contraction of HUA in normal pregnancy. On the other hand, potassium channels do not seem to be involved in 5-HTevoked contractile response of umbilical artery. Taken together our data define a key role for Stat5a/b not only for lymphoid development but also for lymphoid transformation. Stat5a/b is necessary for the initial transformation as well as for leukemia progression. This absolute necessity for the proliferation and viability of Abelson-transformed cells puts Stat5a/b into the spotlight of new therapeutic strategies for the treatment of bcr/ablinduced leukemias.
Dynorphin, with a high selectivity for kappa opioid receptors, is a member of the opioid peptide family. Application of opioid agonists and antagonists revealed crucial effects of the opioid system in numerous physiological functions. However, data obtained are often contradictive, reflecting the complex situation of the cross-activation of 3 receptors through a peptide derived from 3 different precursors. Therefore we investigated prodynorphin knockout mice (DynKO) to establish the effect of prodynorphin deficiency on explorative behaviour in mice. DynKO exhibited higher ambulation in the open field test. Thus, center distance, center time and number of center entries were increased about 2-fold, and number of center rearings about 3-fold. DynKO mice showed also more visits (~2-fold) and more time (~3-fold) spent on open arms of the elevated plus maze test. Significantly higher numbers of entries, distance and time spent in open lit area (ca. 30% higher values) in the light-dark test were observed in DynKO as compared to wild type mice (WT). In contrast to increased explorative behaviour of DynKO under aversive conditions, no differences in motor activity or circadian rhythms were observed in the home cage. The anxiolytic phenotype of DynKO could be mimicked by injection of the selective kappa antagonists norBNI (10 mg/kg, i.p.) or GNTI (3 nmol, i.c.) in WT. Applying the specific kappa agonist U50488H (2.5 mg/kg, i.p.) entirely reversed the anxiolytic phenotype of DynKO. Taken together our data clearly show an anxiolytic phenotype of male DynKO mice. These data are in line with reduced CRH expression in the PVN and attenuated corticosteron serum levels.
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Influence of estrous cycle on explorative behaviour of wild-type and prodynorphin knockout mice Iris Rosskothen
Since several years dynorphin, a member of the opioid peptide family, was suggested to play a regulatory role in numerous functional pathways of the brain. In line with its localization in hippocampus, amygdala, hypothalamus and striatum these functions resemble learning and memory, emotional control and stress response. Male prodynorphindeficient (Dyn KO) mice display an anxiolytic phenotype [see abstract A5]. However, emotional control and stress response depend on hormonal state and differ between sexes. In female rodents mood is influenced also on the estrous state. We now analysed the explorative behaviour in correlation to the estrous cycle in female wild-type (WT) and prodynorphin knockout mice. In the open field test WT mice showed significantly more anxiety during the estrous. This effect is abolished in Dyn KO mice. No differences were seen throughout the other stages. In the elevated plus maze test Dyn KO mice showed a significant anxiolytic phenotype regarding time spent, distance traveled and entries in the open arm at all estrous stages compared to WT mice. In addition, WT mice showed a significant decrease in all parameters during proestrous and estrous. This increased anxiety is attenuated by prodynorphin deficiency. In the lightdark test WT mice showed a decrease in time spent and distance traveled in the lit area during proestrous. In contrast, KO mice behaved relatively stable throughout the stages. Our data indicate an anxiolytic phenotype also in female Dyn KO mice. However, the phenotype is less prominent than in male mice and appears to be dependent on estrous stage and paradigm. It is interesting to note that the influence of the estrous stage appears to be abolished by the prodynorphin deficiency. The functional and pharmacological background will be investigated in further experiments. Neurotransmitter transporters are responsible for terminating signal transmission. hSERT (the human serotonin transporter) is the plasma membrane Na + /Cl − -dependent transporter which is responsible for uptake of serotonin from the synaptic cleft. A previous study has shown that deleting the C-terminus of SERT impaired transporter activity and compromised its delivery to the plasma membrane) [1] . However, this study did not provide to a mechanistic explanation. Alanine-scanning mutagenesis strategy was used in order to delineate which part of the C-terminus of SERT was required for folding of the protein. Pairs of alanine substitutions by site-directed mutagenesis have been produced and we are currently in the process of testing the effect of these mutations on the functional properties and the cellular localization of SERT. The preliminary data show that the mutation in P601G602-AA and R607I608-AA (Sec24 binding site) causes intracellular retention and abolishes uptake and binding.
A7 C-terminal mutation induces a folding defect in the serotonin transporter
P2Y 1 receptor antagonists are being developed as antithrombotics. In the vasculature, P2Y 1 receptors are not only expressed in platelets, but also in the endothelium where they indirectly mediate vasorelaxation. By blockade of these latter effects, P2Y 1 antagonists may cause untoward effects. Here, we investigated whether vascular sympathetic axon terminals also possess P2Y 1 receptors by determining [ 3 H]noradrenaline release from superior cervical ganglion neurons in cell culture. ADP inhibited electrically evoked release, but this effect was reverted into facilitation when either P2Y 12 receptors were blocked by cangrelor or their signalling cascade was interrupted by pertussis toxin. The facilitation by ADP was also observed with K + stimulation in the presence of tetrodotoxin, was mimicked by 2-methlythio-ATP, and was prevented by suramin, reactive blue 2, and MRS2179. The facilitation by ADP was abolished by the phospholipase C inhibitor U73122, but was not affected by cholera toxin to down-regulate G s proteins, by H-7 to block protein kinases, or by thapsigargin to deplete intracellular Ca 2+ stores. In patch clamp recordings, activation of P2Y 1 receptors led to an inhibition of KCNQ channels, but the KCNQ channel modulators retigabine and XE 991 did not alter electrically evoked noradrenaline release or its facilitation by ADP. These results show that presynaptic P2Y 1 receptors mediate facilitation of transmitter release from sympathetic nerve terminals via phospholipase C, and interference with this mechanism by P2Y 1 antagonists can be expected to counteract the previously described vasoconstrictive action of these drugs. Increasing evidence suggests that substance P (SP) and its preferred receptor, namely the neurokinin 1 receptor (NK 1 -R), play an important role in the modulation of stress-related, affective and/or anxious behaviours. Both SP and NK 1 -R are expressed in brain regions critically involved in stress, fear and affective responses such as the amygdala, hippocampus and frontal cortex. In this study we aimed at identifying the types of NK 1 -R-immunoreactive neurones in the basolateral complex of the amygdala according to their content in calcium-binding proteins by dual or triple labelling immunofluorescence. The basolateral amygdaloid complex consists of the lateral (LA) and basolateral (BL) nuclei, which are believed to be cytoarchitectonically and cytochemically similar. Our study reveals that in adult male Sprague-Dawley rats, 38.7 ± 6.7% of NK 1 -R immunopositive LA neurones (124/331) co-express parvalbumin, representing 15.2 ± 3.4% (124/820) of parvalbumin-immunopositive neurones. Conversely, in the BL no coexistence between NK 1 -R (293 neurones counted) and parvalbumin (2,385 neurones counted) expressing neurones was detected. In addition, we found that 32.4 ± 3.8% of NK 1 -R-immunoposititive LA interneurones (33/104) co-express calbindin-D28k, that is 6.0 ± 1.7% (33/626) of the total number of calbindin-D28k-immunoreactive neurones. On the other hand, in the BL a large number (72.3 ± 6.9%) of NK 1 -R-immunopositive neurones (109/149) were found to co-express calbindinD28k, representing 6.8 ± 1.3% of all calbindin-D28k-labelled neurones. We also found a lack of coexistence between NK 1 and CR in both lateral and basolateral amygdala. These results suggest that interneurones in the LA and BL amygdala differentially express molecules involved in cell signalling and indicate a distinct organization in local interneurones. The BL resembled the hippocampal CA1 region, in which NK 1 -R-expressing neurones do not coexist with parvalbumin. The polyphenol resveratrol (RV) was previously shown by us to inhibit the angiotensin (Ang) II and epidermal growth factor (EGF)-mediated phosphorylation of Akt in vascular smooth muscle cells (VSMC) and fibroblasts. In fibroblasts, RV was shown to activate the SH2 domain containing phosphatase 2 (Shp2) leading to subsequent dephosphorylation of Gab1 and an impaired recruitment of the phosphoinositide 3-kinase (PI 3 K) to this adapter protein at the EGF receptor. The present study aims (i) to verify a role for Shp2 regarding the Akt inhibitory effect of RV in VSMC, and (ii) to examine whether the RV effect on Akt phosphorylation depends on a redox sensitive mechanism. An siRNA knock-down of Shp2 protein levels to 50% in VSMC still allowed RV to significantly inhibit EGF-as well as Ang II-mediated Akt phosphorylation, though less pronounced compared to control cells, neither verifying nor denying Shp2 as a potential target of RV in VSMC. EGF and Ang II are reported to require reactive oxygen species (ROS) to transduce their signal probably by inactivating redox-sensitive phosphatases. Indeed, intracellular ROS (measured by H 2 DCFDA) was significantly induced by Ang II and EGF stimulation, and RV pre-treatment kept intracellular ROS even below basal control levels. Pre-treatment of VSMC with the antioxidant N-acetyl cystein (NAC) and flavoprotein inhibitor diphenylene iodonium (DPI) followed by stimulation with Ang II and EGF, respectively, showed that NAC and DPI were able to inhibit Ang II-mediated Akt phosphorylation.
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However, they failed to inhibit phosphorylation of Akt upon stimulation with EGF. This confirms that Ang II signalling requires ROS to transactivate the EGF receptor, whereas the signalling downstream of the EGF receptor towards Akt seems to occur largely independently from ROS. Since RV was shown to interfere downstream of the EGF receptor with the PI 3 K/Akt pathway, we conclude that Akt inhibition by RV most likely occurs redox-independently. Thus, if Shp2 is a target for RV, it seems not to be redox-regulated by RV. . Generally, the activity of GPCRs is coordinated by receptor signaling, receptor desensitization and receptor resensitization. The latter two mechanisms are typically associated with the sorting of the GPCRs between degradation or recycling pathways and are highly regulated. Several sorting proteins have recently been identified, for example the G protein-coupled receptorassociated sorting protein-1 (GASP-1). GASP-1 was originally found to target delta opioid receptors (DORs) to lysosomes and hence a degradative pathway. This study shows that GPR55 can internalize after ligand activation and is subsequently targeted to intracellular vesicles of the lysosomal compartments. This result and the close similarity of GPR55 to the cannabinoid receptor CB 1 -which is targeted to lysosomes via the GASP-1 protein -suggested that GASP may be involved in targeting GPR55 to lysosomes. In fact, here we show that the C-terminus of GPR55 binds GASP-1, cGASP-1 (the C-terminal part of GASP-1) and GASP-2 (the closest homologue to GASP-1) in vitro. Both GASP-1 and cGASP-1 show a high affinity to the C-terminus of GPR55 in vitro, with a ~2-fold higher affinity for GASP-1 when compared to the DOR. Interestingly, the GASP-2 isoform has the highest affinity for GPR55 with ~85% when compared to GASP-1 and cGASP-1 (~80%). This study provides first evidence that the novel cannabinoid receptor GPR55 is targeted to lysosomes after prolonged agonist stimulation and this mechanism is likely regulated by members of the newly discovered G proteincoupled receptor-associated sorting proteins, i.e GASP-1 and GASP-2. The subiculum is the main output region of the hippocampus receiving input from the CA1 region and projecting to deep layers of the entorhinal cortex (EC), septum, mamillary nuclei, and the amygdala. It remains largely preserved in temporal lobe epilepsy (TLE) and therefore may be importantly involved in the generation of epileptic activity arising from the hippocampus. We characterized neurons of the subicular-EC complex and its projections in the kainic acid (KA) model for TLE using neuropeptides, calcium binding proteins, GAD-67 and the vesicular GABA and glutamate transporters as markers. We observed severe losses of interneurons and principal neurons in layer III of the EC and in the proximal subiculum accompanied by signs of reactive gliosis. The number of parvalbumin-ir interneurons was reduced in the subicular pyramidal cell layer and the deep layers of the EC. After 28 d the number of calretinin-ir neurons was reduced in EC layers III to VI, as was the diffuse calretinin-ir in the subiculum molecular layer and the EC, suggesting degeneration of respective calretinin containing projections. In all parahippocampal areas, increases in NPY mRNA in pyramidal cells and of NPY-ir axons were seen at the late intervals after KA. In the molecular layer and layer I of the EC, diffuse labeling for SOM-ir overlapped with that of NPY. The number of GAD67-ir interneurons was reduced in the inner molecular layer and pyramidal layer of the subiculum and in the EC at late timepoints, but also diffuse labeling for GAD67 and VGAT was enhanced in the molecular and pyramidal cell layers of the subiculum and in EC layer I. Our data indicate losses in neurons projecting from the EC to the subiculum. Similarly, projections from the subiculum to the deep layers of the EC seem to degenerate. Current pharmacotherapy of anxiety disorders and depression mainly targets GABA A receptors and monoamines such as the serotonin and noradrenaline systems, respectively. They are effective, but an improvement of their therapeutic efficacy in regard of therapeutic onset, side effects and the number of treatment responders is desired. Here, we tested the sensitivity of a mouse line characterised by extremely high levels of trait anxiety and co-occurring depression (HAB) to the selective neurokinin-1 receptor (
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amine using a battery of established tests revealing anxiety-and depression-related behaviours. Chronic administration of the NK 1 R antagonist via the drinking water increased the time spent in the brightly lit compartment of the light/dark test and attenuated fear responses in a classical cued fear conditioning paradigm in male and female HAB animals. In addition, the enhanced immobility times of HABs displayed in the forced swim and tail suspension tests were reduced. These findings indicate a clear anxiolytic and antidepressant effect of chronic NK 1 R antagonist treatment in HAB animals which have not responded to any classical, clinically effective pharmacotherapy tested so far including paroxetine or diazepam. Moreover, they raise the possibility of a hyperactive substance P/NK 1 R neurotransmission in the HAB line. To test this hypothesis, we performed in situ hybridisation studies in the forebrain of HAB mice, their low anxiety/depression (LAB) counterparts and unselected CD1 (NAB) mice. Indeed, the abundance of Tac1 mRNA, the precursor of substance P was elevated in the habenula and ventromedial hypothalamus of HAB compared to NAB and/or LAB mice suggesting that up-regulated transcriptional processes in the substance P system may contribute to the enhanced anxiety-and depression-related behaviours of HABs. Chronic NK 1 R antagonist treatment did not alter the high Tac1 mRNA expression of HAB mice. In addition, the HAB vs. the other two lines displayed reduced BDNF mRNA expression in the dentate gyrus and increased metenkephaline mRNA expression in the hippocampal CA3 region which both were not altered following chronic NK 1 R antagonist treatment. Taken together, the present results indicate that the HAB mouse line may represent a unique, clinically relevant model to study drug targets and underlying neurochemistry with potential clinical benefit in treatmentresistant pathological anxiety and co-occurring depression. Acknowledgements Supported by the FWF W1206-B05 (NS). 
A20
Methods
In order to reveal structural features of the domain IV S6 segment (DIV-S6) relevant to FI, we produced serial replacements by cysteines of residues 1575-1591 in DIV-S6 of the rNa V 1.4 channel ("first hit"). Furthermore, a critical residue within the selectivity filter of the rNa V 1.4 channel, K1237, was replaced by the negatively charged glutamate ("second hit"). Previously, this mutation has been shown to produce dramatic alterations in permeation and gating properties of the wild type channel. The constructs were expressed in Xenopus laevis oocytes and studied by two electrode voltage clamp.
Results
In the background of serial cysteine replacements in DIV-S6, the mutation K1237E shifted the half-point of FI to more negative potentials in all but two constructs. Only in the DIV-S6 background of F1579C and Y1586C was the half-point of FI shifted to more positive potentials upon addition of K1237E. This is remarkable, because both residues have previously been implicated in destabilization of FI and in binding of local anesthetics to the channel. A fast Fourier analysis of the serial "second hit" changes in the voltageindependent free energy of FI revealed a periodicty of gating perturbations by K1237E consistent with an alpha-helical arrangement of DIV-S6. Such periodicity could not be found if the voltage-dependent charge movement associated with FI-perturbations by K1237E was analyzed.
Conclusions
We conclude that residues F1579 and Y1586 in DIV-S6 serve to stabilize FI. Furthermore, the movement of the inactivation gate during FI appears to be associated with an alpha-helical arrangement of DIV-S6. The process of cancerogenesis is driven by the hierarchical accumulation of genetic changes. Hence, beside the deregulated expression of an oncogen, additional genetic defects have to take place in order to transform a normal cell into a tumor cell. In case of Burkitt's lymphoma, a c-mycdriven haematological tumor, two predominant so called 2nd hits have been identified. First, loss-of-function mutations in the p19-Mdm2-p53 tumor suppressor pathway, and second, the over-expression of the anti-apoptotic protein Bcl-2. So far it is not known whether these two different 2nd hits translate into cell-autonomous effects or the ability of the immune system of recognizing and destroying the tumor cells. Our studies revealed that neither over-expression of Bcl-2 nor loss-of-function mutations in the p19-Mdm2-p53 tumor suppressor pathway alters any analysed cellautonomous effect significantly. However, we could specify an impact of these additional genetic lesions on the interaction between immune system and tumor cells. We were able to show that tumor cells over-expressing Bcl-2 can be eliminated by the immune system more effectively than ones with p19-Mdm2-p53 tumor suppressor pathway malfunctions. These data are in line with the analysis regarding 2nd hits of primary tumor samples obtained form an animal model of Burkitt's lymphoma. This analysis showed a clear survival advantage of mice suffering from tumors over-expressing Bcl-2. Taken together, our studies provide basic knowledge concerning the influence of the 2nd hit on the interaction between immune system and tumor cells, which might have prognostic value for immune based cancer therapies. . Moreover, we discovered that GPR55 activation leads to an efficient activation and nuclear translocation of nuclear factor of activated T-cells (NFAT) transcription factor family. We next tested a panel of known cannabinoid ligands and discovered that GPR55 is activated by AM251, which is a known inverse agonist on the CB 1 R. In addition, the CB 1 R antagonist SR141716A (rimonabant) was able to induce GPR55-mediated signaling, although it was less potent than both AM251 and LPI. LPI was also able to induce the internalization of GPR55. Lastly, we found that CB 1 R and CB 2 R co-localize with GPR55 on the surface of HEK cells and also can block the NFAT activation mediated by GPR55. Morphinans play an important role among therapeutically valuable opioids. They include powerful pain relieving agents such as naturally occurring alkaloids (e.g. morphine, codeine), semisynthetic derivatives (e.g. oxycodone, oxymorphone, buprenorphine), and synthetic analogues (e.g. levorphanol, butorphanol). These opioid drugs produce their biological actions through three receptor types, μ, δ and κ, belonging to the family of seven transmembrane G protein-coupled receptors. All three opioid receptors are located in the central and peripheral nervous systems of many species including human. Morphine and related opioids currently prescribed as potent analgesics for the treatment of severe pain produce their analgesic activity primarily through their agonist action at μ opioid receptors, which is the main receptor type targeted for pharmacotherapy of pain. Despite their widespread use, opioid drugs have a number of severe side effects including respiratory depression, emesis, sedation, constipation, tolerance, and physical dependence. Consequently, a great deal of effort was spent trying to develop safer, more efficacious and non-addicting compounds, with the goal of an improved therapeutic index. Optimal physicochemical properties are often an important consideration for the development of bioactive molecules as therapeutic agents. Therefore, a significant aim in medicinal chemistry research and drug development is to predict the behavior of targeted molecules based on their physicochemical features. This task, however, cannot be accomplished without correlating and understanding the differences in the physicochemical and pharmacological properties of existing opioid morphinans. Toward this goal, we performed a comparative study on physicochemical properties and biological activities of well-known opioid morphinans such as the naturally occurring alkaloid morphine, and semisynthetic analogues e.g. oxymorphone. Besides the classical and clinically relevant opioid analgesics, synthetic morphinans developed by our group were included in the study, the 14-O-methyl derivative of oxymorphone and its 5-methyl substituted analogue, 14-methoxymetopon. The major physicochemical parameters (pK a , logP and logD) have been experimentally determined using a Sirius PCA200/Cheqsol Instrument. In vitro binding affinities and selectivities to opioid receptors were determined in rodent brain membranes using binding assays. Analgesic potencies were evaluated after subcutaneous administration to mice using tail-flick and hotplate tests. The structure-activity relationship observations, combining physicochemical and biological data, will be discussed. Altogether, the present study indicate that specific structural elements are required to confer high affinity/selectivity for μ opioid receptors and potent agonist and analgesic activity in the morphinan class of opioids, and are important in drug development. Pain constitutes a major public-health problem with an impact on both the individual and the society that is still inadequately treated. All clinically used opioid analgesics for severe acute and chronic pain, e.g. morphine, fentanyl and oxycodone, are agonists activating central μ opioid receptors. Their clinical use is associated with a number of adverse actions, such as respiratory depression, sedation, nausea, constipation, tolerance and addiction. One of the major aims of medicinal chemistry and opioid pharmacology is to develop opioids with high affinity and/or selectivity for the μ opioid receptor, exhibiting a favorable dissociation between analgesia and the occurrence of side effects. 14-Methoxymetopon, designed by our group, was described as a highly potent and selective μ opioid agonist with an unusual pharmacological and functional profile, being genuinely safer than the "gold standard pain-killer" morphine. With the aim to identify and develop scientifically proven opioid drugs with a reliable target-oriented pharmacological profile, established efficacy and favorable safety index, a new analogue of 14-methoxymetopon, containing a benzyl substituent at position 5, was investigated for its in vitro biological and in vivo pharmacological activities. Binding affinities and selectivities to opioid receptors were determined in rodent brain membranes using competition binding assays. Analgesic activity after subcutaneous (s.c.) administration was assessed in mice using tail-flick and hot-plate tests. The rotarod test was used to evaluate the drug effect on motor coordination. In vitro binding studies indicated that the 5-benzyl analogue of 14-methoxymetopon displayed high affinity and selectivity at the μ opioid receptor. It showed a significant increase in affinity (20-fold) at the μ receptor as compared to that of morphine. The 5-benzyl derivative produced dose-dependent analgesic effects in the tail-flick and hot-plate tests after s.c. administration to mice. The antinociceptive dose necessary to elicit a 50% effect (ED 50 ) was 43 µg/kg in the tail-flick test and 53 µg/kg in the hotplate test. Compared to 14-methoxymetopon, the new analogue showed comparable antinociceptive potency, while it was about 50-fold more active than morphine. No significant impairment of the motor performance was induced by the novel opioid. These findings show that introduction of a 5-benzyl substituent into 14-methoxymetopon did not significantly affect the in vitro and in vivo pharmacological properties compared to the parent compound. The interesting pharmacological profiles of this class of morphinans will serve as a basis for our continuing exploration of potent opioid analgesics for the pharmacotherapy of pain.
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A24 Modulation of multidrug resistance proteins by statins in human neuroblastoma
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both animals and human. Receptor type selective opioid agonists and antagonists are of interest both as pharmacological tools and as potential therapeutic agents for the treatment of pain, addiction, constipation or immunological diseases. During the past 3 decades, one of the major aims of medicinal chemistry and opioid pharmacology has been to develop opioids with high affinity and/or selectivity for each of the three receptor types. In this study, 14-alkoxy analogues of naltrindole, naloxindole and naltriben with different benzyloxy substitution in position 14 have been investigated to elaborate on structure-activity relationships (SAR) of the morphinan class of compounds.
To this aim, several 14-benzyloxy substituted indolo-and benzofuromorphinans were prepared by multi-step synthesis using naloxone and naltrexone as starting materials. Binding affinities and selectivities to opioid receptors (μ, δ and ĸ) were determined using in vitro binding assays with rodent brain membranes employing selective opioid radioligands. Examination of the chemical structure and opioid binding profile i.e. affinities and selectivities reveals certain SAR for the investigated compounds. Opioid binding affinity was sensitive to the character and length of the substituent in position 14. Introduction of 14-benzyloxy groups resulted in reduced affinity and selectivity for the δ receptor. The replacement of the N-allyl by an N-cyclopropylmethyl group in position 17 resulted in increased δ affinity without affecting δ receptor selectivity. The results of the present study indicate that position 14 of indolo-and benzofuromorphinans represents a critical site that could be a trigger to develop opioid compounds with increased δ affinity and/or selectivity. These findings provide further evidence that the nature of the substituent at position 14 has a major impact on the abilities of morphinans to interact with opioid receptors. Secretogranin II (SgII) belongs to the family of chromogranins, which are widely expressed in large densecore vesicles (LDV) of nerves and neuroendocrine tissues. In LDV SgII is processed to smaller peptides, like secretoneurin (SN). SN was initially described in our lab [1] and has been established as a novel biologically active neuropeptide linking nerves, blood vessels and the immune system. SN releases dopamine and dynorphin from rat striatal slices, potently and specifically attracts monocytes, eosinophils, dendritic and endothelial cells towards a concentration gradient and acts as an angiogenic and vasculogenic cytokine comparable in potency to VEGF. SN contributes to neurogenic inflammation and might play a role in the irritative response in the eye, as it innervates a wide range of ocular tissues. The role of SN in hypoxia-driven induction of neo-vascularization in ischemic diseases like cerebral ischemia or in solid tumours will be subject of studies with a conditional knockout mouse for the secretogranin II gene. For these studies, a targeting vector was generated in our lab. In classical knockout animals the target gene is disrupted by either deleting parts of the gene, or by insertion of foreign DNA sequences into the target gene by site-specific homologous recombination. This genetic rearrangement is present in each cell of the animal right from the start. In conditional knockout animals, the structure and function of the gene of interest is only minimally altered. The gene of interest gets flanked by loxP sites, which serve as cleavage site for the Cre recombinase.
A31 TRPC3 as a key player in electrical remodelling of atrial myocardium
In the presence of this enzyme, the gene will be excised precisely while other cells without Cre recombinase remain unaffected. 
Materials and methods
Rotenone at a dose of 1.5 mg/kg i. p. or vehicle (natural oil, 1 ml/kg) was administered to male Sprague-Dawley rats daily for 10, 20, 30 and 60 days and NO and LPO were measured in the frontal and prefrontal cortices, striatum and nucleus accumbens (NAc). NO generation was directly measured using electron paramagnetic resonance spectroscopy. Specific indexes of LPO (i.e., thiobarbituric acid reactive substances, TBARS) were measured spectrophotometrically. Catalepsy was tested by measuring the descent latency after 30 and 60 days using a bar and grid test. Results NO levels in all studied brain structures of rats after the first rotenone injection were not different from those of the control group. In striatum and frontal cortex the level of NO was increased on day 30 and day 60. In our study on day 1 and 20 there were slight increases of TBARS in the striatum and frontal cortex, but on day 30 and 60 the amount of TBARS was two times greater as compared to control in these regions. Rotenone-treated animals showed a prolonged descent latency as compared to control animals after 60 injections of rotenone only. An increase of descent latency from day 30 to 60 was not observed.
Conclusions
The findings indicate that chronic administration of rotenone at the low dose 1.5 mg/kg significantly enhances the NO generation in all studied brain areas, especially in the NAc and striatum. Moreover, the results provide the first direct evidence that rotenone increases NO tissue levels. The results of this study should advance the understanding of the mechanism of action for pesticides in the pathogenesis of PD.
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Identification of amino acid residues relevant for gating and permeation of the cation channel TRPC3 Hannes Schleifer, Michael Poteser and Klaus Groschner Department of Pharmacology and Toxicology, Institute of Pharmaceutical Sciences, University of Graz, 8010 Graz, Austria E-Mail: klaus.groschner@uni-graz.at
Background and methods Mammalian TRPC3 cation channels are activated through phospholipase type C (PLC)-dependent pathways and play a fundamental role in a variety of physiological functions. So far, only little information is available on structural determinants of channel function, especially domains involved in channel gating and permeation. Therefore, we set out to modify putative permeation-relevant residues of this ion channel by site-directed mutagenesis and analyzed the impact of these mutations on channel functions using a HEK293 expression system and the patch clamp technique. Results A triple mutation of the native glutamate or aspartate residues to alanin (E630A, D639A and E644A) within the putative pore region resulted in spontaneous activity and currents with altered (linear) IV-relations, while the principle removal of negative charges at these positions (E to Q and D to N) failed to induce detectable changes in channel function. Single exchange of a negative amino acid in this region (D639A) as well failed to change IV-relations. Surprisingly, double substitution of E by Q near the putative external vestibule (amino acid 615 and 616) eliminated the sensitivity of channels to PLC-mediated activation.
Conclusions
In conclusion, our data suggests an unexpected role of amino acid residues within the outer vestibule of TRPC3 channels in terms of gating and selectivity. These results give rise to a remodelled picture of structure-function relations in TRPC channels.
Benzodiazepine site agonists modulate the firing pattern of neurons via GABA A receptors and by that influence the activity of the network in which they participate and cause appropriate changes in behaviour. Since the amygdala is involved in regulating anxiety, it can be expected that GABA A receptors located in this brain region contribute to the anxiolytic effects of benzodiazepine site agonists. Here we take advantage of an in vivo mouse model [1] in which a Phe to Ile point mutation was introduced into the gene coding for the GABA A receptor γ2 subunit. This γ2F77I mutation, which was also flanked by loxP sites, affects only the benzodiazepine binding site of the respective receptors, and mice carrying this mutation no longer are sensitive to certain benzodiazepine site agonists but are otherwise normal. Here we aim to selectively replace the "benzodiazepine insensitive" mutated γ2F77I subunit by a GFP-labeled native one in the amygdala of γ2F77Ilox mice by a stereotaxic injection of recombinant adeno-associated viral (rAAV) vectors expressing Cre-recombinase and GFPlabeled wild-type γ2 subunits. It has been demonstrated previously that the replaced wild-type subunits combine with endogenous subunits to form completely assembled receptors with normal subcellular distribution. Then only those amygdala neurons expressing the GFP-labeled wildtype γ2 subunits can be modulated by a systemic application of these benzodiazepine site agonists and any behavioural effects observed with these drugs must have been generated via these neurons. In this report we present a preliminary characterization of the newly developed mouse model demonstrating the correct expression of We have recently characterized the coumarin scopoletin as a compound which fits a pharmacophore model of AChE inhibitors and enhances the release of ACh in rat brain [1] . Now, a comprehensive study was carried out in order to investigate the effects of scopoletin on learning and memory, on release of ACh from synaptosomes and on hippocampal long-term potentiation (LTP) in order to uncover the mechanism of action.
Materials and methods
Learning and memory:
The effect of scopoletin on learning and memory was tested on normal and scopolamineamnestic mice with the T-maze alternation and the object recognition test. [2] . In the present study we investigated whether LPS challenge has long-term effects on anxiety-like and depression-related behaviour and whether these effects are altered in Y 2 −/− and Y 4 −/− mice. Background When the myocardium is injured by an acute infarction, a fibrous, non-contractile scar develops, because mature cardiac tissue cannot effectively regenerate. In patients this often results in congestive heart failure, one of the major health problems in the developed world. Although multipotent cardiac stem cells, which could support myocardial regeneration, were recently identified, their limited availability prevents therapeutic applications. More readily available stem cell populations derived from other tissues, such as undifferentiated skeletal myocytes (myoblasts) or bone marrow-derived adult stem cells, have been shown to be capable of repairing cardiac damage in animal models. These cell types, however, have a very limited capacity to transdifferentiate into functional cardiomyocytes after transplantation into the heart. This fact certainly hampers their beneficial therapeutic effects. A strategy to overcome this problem would be the induction of cardiomyogenic function in stem cells prior to transplantation. Here, we tried two different in vitro strategies to achieve this goal in skeletal myoblasts.
Materials and methods
Mouse C2C12 skeletal myoblasts were incubated in differentiation media preconditioned by primary cardiomyocyte cultures (cardiac preconditioning), or treated with the cardiomyogenic small molecule cardiogenol C for 2-14 days. Thereafter, their electrophysiological properties were measured using the whole cell patch clamp technique, and compared with those of untreated control cells.
Results
Simulation of a cardiac cell environment by "cardiac preconditioning" altered the Na + current activation and inactivation properties of C2C12 cells from skeletal muscle to more cardiac-like ones. Tetrodotoxin and RT-PCR experiments suggest that an upregulation of the expression of the cardiac sodium channel isoform Na V 1.5 versus the skeletal muscle isoform Na V 1.4 is responsible for the observed changes in sodium current function. Of the 5 known subtypes of mAChRs, M 2 , M 3 , and M 4 have been reported to act as inhibitory presynaptic receptors in the nervous system, in general, and in sympathetic neurons, in particular. M 1 receptors, in contrast, have rather been viewed as facilitatory presynaptic receptors. In superior cervical ganglion (SCG) neurons, M 1 receptors are well known to inhibit KCNQ channels. Previously, we were able to show that non-presynaptic M 1 receptors in SCG neurons enhance noradrenaline release through an inhibition of KCNQ channels. However, M 1 receptors also mediate an inhibition of voltage-activated Ca 2+ channels, which represents the predominant mechanism of presynaptic inhibition. Hence, presynaptic M 1 receptors may exert inibitory presynaptic modulation. To test this possibility, we performed experiments on rat superior cervical ganglion neurons. In primary cultures tritium overflow was assayed to investigate the release of The A 2A adenosine receptor is a G protein-coupled receptor which desensitizes upon prolonged agonist stimulation. In order to understand the biological function of its unusually long C-terminus, we screened a human brain library for proteins capable of binding to the last 120 amino acids of the A 2A receptor. We identified a guanine nucleotide exchange factor for the small G protein ARF6 (ARNO/cytohesin-2) as a binding partner. In this study, we investigated the impact of ARNO on A 2A receptor signaling in rat pheochromocytoma (PC12) cells. These cells express the A 2A receptors endogenously. We created cell lines with inducible expression of ARNO or its catalytic inactive mutant E156K. Neither wild type ARNO nor the mutant had an effect on receptor expression, signaling via adenylyl cyclase after activation or long-term de-and resensitization kinetics. In order to investigate effects of ARNO on A 2A receptor shortterm de-and resensitization we employed a FRET-based sensor to measure changes in cAMP in real time. Cells were transfected with plasmids encoding the regulatory and The principle of "fluorescence resonance energy transfer" (FRET) has been exploited in cell biology to demonstrate the interaction of two proteins in living cells. FRET is highly specific and sensitive and allows for the online recording of events that modulate the interaction. We here demonstrate that FRET-based sensor molecules represent an alternative in monitoring receptor-dependent signalling. We have used a sensor for the second messenger cAMP to assess cellular formation of cAMP and to follow receptor activity and its desensitization with sufficient temporal resolution. Compared to standard biochemical means of determining cAMP, which require a large number of cells, the sensor records transient events localized in single cells. We show in primary neurons that cAMP formation triggered by the A 2A adenosine receptor occurs in a manner similar to that observed in established models from cell culture. Another way to apply FRET in signal transduction research is in determining the conformational change of signalling proteins. One example is SAP102 (synapse associated protein of 102 kDa) and its binding partner mPINS (mammalian partner of inscuteable). Both proteins are known to form intramolecular bonds and therefore exist in an "open" and "closed" conformation which presumably reflects different activity states in a signalling pathway. For instance, binding of mPINS to the heterotrimeric G protein α subunit Gα i leads to an open conformation. With the use of constructs, where the conformationally active protein regions are tagged with FRET-partner fluorophores, we show that a G protein-coupled receptor may impinge on the folding of these proteins. This may provide a tool to scan for receptors capable of activating an effector as specific as mPINS. Selective serotonin reuptake inhibitors (SSRIs) have been observed to drive programmed cell death in Burkitt lymphoma cells. Further studies, however, showed that SSRIs induce apoptosis with little, if any, appreciable selectivity. Actually, the selectivity appears to be so low that SSRIs can kill protozoa such as Trichomonas vaginalis. Although the serotonin transporter SERT was initially considered as SSRI target in inducing programmed cell death, this concept has been rejected repeatedly. Nacetylated versions of SSRIs, which are not capable of inhibiting serotonin reuptake anymore, were shown to kill cells in concentration ranges comparable to those of their non-acetylated original versions. Our working hypothesis is that SSRIs induce cell death via activation of the endoplasmic reticulum stress response/unfolded protein response (UPR). To address this hypothesis, we performed a luciferase reporter assay (in HEK293 and HeLa cells), in which the firefly luciferase gene is under the control of the promoter for glucose-regulated protein of 78 kD (GRP78), an endoplasmic reticulum (ER) chaperone mainly expressed during the UPR. Several SSRIs (paroxetine, fluvoxamine, fluoxetine and citalopram) and their N-acetylated versions induce GRP78 expression with steep concentrationresponse curves, comparable to those obtained for killing cells. SSRIs also trigger activation of caspase 3/7, as observed with a caspase 3/7-dependent fluorescent substrate, and expression of the endoplasmic reticulum stress protein C/EBP-homologous protein (CHOP-10). Our results suggest that SSRIs induce cell death via the UPR, and further experiments are designed to strengthen our hypothesis. We will also investigate, if this effect is conserved throughout species (e.g. in Trichomonas vaginalis). Administration of amphetamines (AMPH), induces the reversal of substrate transport. It has been repeatedly shown that inward and outward transport can be independently regulated; phosphorylation of key residues in the amino-terminus is thought to be the responsible mechanism. In our study, we provide evidence for a novel intracellular regulation mechanism of SERT. Depletion of phosphatidylinositol-4,5-bisphosphate (PIP2) reduced AMPH-induced SERT-mediated substrate release specifically. This effect was limited to SERT-mediated efflux because SERT-mediated reuptake was completely unaffected. PIP2 depletion was achieved by activation of phospholipase C (PLC) upon application of 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide (m-3M3FBS; 25 µM), a direct and potent PLC activator. Efflux was determined in a superfusion system that allows for measurement of AMPH-triggered fractional release rates of substrate efflux. Preincubation (10 min) of SERT wild-typeexpressing cells with m-3M3FBS led to a significant and concentration-dependent reduction of AMPH-induced efflux. This effect was largely blocked by co-application of U73122 
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Results
The platelet reactivity index (PRI in the VASP assay, normal range 69-100%) was higher in patients on both clopidogrel and calcium channel blockers (61%) as compared to patients on clopidogrel without calcium channel blockers (48%). The absolute difference was 13% (95%CI: 6-20%; p = 0.001) and the relative difference approached 21%. A reduced effect of clopidogrel (PRI >69%) was seen in 40% of patients with concomitant calcium channel blocker treatment compared to 20% without (χ 2 -test: p = 0.008).
Intake of calcium channel blocker remained an independent predictor of reduced platelet inhibition by clopidogrel after adjustment for cardiovascular risk factors. This corresponded to an increased platelet aggregation of similar magnitude (p < 0.05) and was associated with adverse clinical outcome. In vitro incubation with calcium channel blockers (nimodipine, verapamil, amlodipine and diltiazem) did not alter the PRI or the ADP-induced platelet aggregation of patients on clopidogrel. This indicates that the negative effect occurs in vivo, conceivably at the level of the CYP3A4 cytochrome. Conclusion Co-administration of calcium channel blockers is associated with a decreased platelet inhibition by clopidogrel. 
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Materials and methods
A young (n = 7, mean age: 28.0 ± 3.8 years) and an aged group (n = 6, mean age: 69.4 ± 8.5 years) of healthy volunteers underwent dynamic VPM PET scans and arterial blood sampling. Radiolabelled metabolites of VPM were quantified by a previously described combined solid-phase extraction/HPLC protocol [1] . A whole-brain grey matter region was defined by using the Hammersmith n20r49 brain atlas [2] . The DV of VPM was estimated by using a 2-rateconstant-1-tissue-compartment model [1] .
Results
Mean DVs (± standard deviation) of VPM were 0.50 ± 0.08 for the young and 0.63 ± 0.13 for the aged group (+27% for the aged group, p = 0.04, 2-tailed t-test). There was no significant difference in VPM metabolism between the young and the aged group (area under the curve of the fraction of polar [ 11 C]metabolites of VPM versus time in arterial plasma:
12.7 ± 2.4 and 14.1 ± 3.6 for the young and the aged group, respectively, p = 0.19, 2-tailed t-test).
Conclusion
Our data confirm previous results that older subjects show significantly decreased P-gp function in the BBB [1, 3] . Decreased P-gp function can lead to increased accumulation of toxins and drugs in the aging brain and could thus be a risk factor for the development of neurodegenerative disease. 
Background
Microdose studies comprise the administration of a single subpharmacological dose of a carbon-14 ( 14 C)-labelled drug (<100 µg) to humans in order to describe the drug's pharmacokinetic (PK) profile in blood by means of accelerator mass spectrometry (AMS) analysis. As most drugs exert their pharmacological effect in tissue rather than in the central (blood) compartment, methodology is needed that allows for extending PK analysis from blood to different tissue compartments in microdose studies. In this pilot study we combined AMS analysis with the non-invasive nuclear imaging technique positron emission tomography (PET) in order to measure the PK profile of the model drug verapamil, at the same time in plasma and in brain tissue. Because dose linearity of PK parameters is a prerequisite for the prediction of therapeutic-dose from microdose PK data, we assessed the PK parameters of verapamil at two different doses.
Materials and methods
Six healthy volunteers received a microdose (0.05 mg) and a therapeutic dose (80 mg) of verapamil, labelled both with 14 C and the positron emitter carbon-11 ( 11 C), in a randomised cross-over fashion. The brain distribution of verapamil was measured by means of PET imaging whereas the drug's plasma PK was determined with AMS analysis. PET data were analysed by kinetic modelling in order to estimate the rate constants for the transfer of verapamil across the blood-brain barrier (BBB).
Results
We were able to simultaneously measure the plasma and brain tissue PK of verapamil by means of combined AMS and PET analysis. 
Retinal arteries and veins showed a significant dilatation after administration of bosentan in both groups (+5% to 8%). Retinal blood velocity and retinal blood flow increased up to +45% after administration of bosentan in both patients and healthy subjects. Administration of bosentan increased choroidal (+12% to 17%) and optic nerve head blood flow (+11% to 24%) in both groups. The effect of bosentan on ocular blood flow parameters was comparable between the two groups.
Conclusions
The data of the present study indicate that dual inhibition of endothelin receptors increases ocular blood flow in patients with glaucoma and healthy subjects. Further studies are required to study the dose-response relationship of this effect and to characterize the role of endothelin receptor subtypes. 
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Background
Normalization of blood flow is required to salvage ischemic tissues, but might paradoxically cause reperfusion injury. The aim of this study was to determine whether restoration of skeletal muscle high energy phosphates after ischemia is affected by post-ischemic vessel stenosis. Methods Leg ischemia was induced by a cuff on one thigh for 20 minutes and muscle high energy phosphates depleted by lower leg exercise (n = 5 healthy male subjects). After calf ischemia, the cuff was either deflated or air pressure maintained at 20 mmHg below systolic pressure for 5 min (stenosis). Measurements of high-energy phosphates in gastrocnemius muscle were performed with a 3T spectrometer. 31 P and 1 H spectra were acquired as an estimate of myocellular concentrations of phosphocreatine (PCr) and inorganic phosphate (iP).
Results
PCr concentrations decreased to 31% ± 16% during ischemic exercise (p < 0.001) and iP levels increased in parallel. While PCr re-established within 2 min after cuff deflation, no recovery was detectable when blood flow was impaired in the reperfusion phase. Discussion Muscle phosphate recovery depends on normalization of blood flow. These data indicate that intensified strategies to re-establish flow conditions are required for residual myocellular function after transient ischemia.
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In vivo profile of the human leukocyte microRNA response to endotoxemia 
Material and methods
Leukocyte RNA was isolated from venous blood samples obtained from healthy male volunteers before and 4 hours after LPS-infusion. After fluorescence labeling, RNA samples were hybridized to microarrays containing capture probes for measuring the abundance of more than 600 human miRNAs. Target genes were predicted for differentially expressed miRNAs and then compared to changes in genome-wide expression levels, which had been established in a previous study.
Results
Data analysis revealed that five miRNAs consistently responded to LPS-infusion, four of which were downregulated (miR-146b, miR-150, miR-342, and let-7g) and one was up-regulated (miR-143). By correlating to measured LPS-induced changes of the leukocyte transcriptome, we next searched for predicted target genes, whose stability might be under (co-)control by these miRNAs. We found that the rapid transcriptional activation during acute inflammation of select genes, such as the gene encoding interleukin-1 receptor-associated kinase 2 (IRAK2) might be facilitated by decreased levels of LPS-responsive miRNAs. The increased level of miR-143 might be associated with the pronounced down-regulation of the B-cell CLL/lymphoma 2 (BCL2) gene expression during LPS endotoxemia, and could further be involved in the translational silencing of several other predicted inflammation-related target genes. Conclusions This is the first in vivo study to demonstrate relative abundance of miRNA levels in peripheral blood leukocytes during acute LPS-induced inflammation. The miRNAs and their potential target genes identified herein contribute to the understanding of the complex transcriptional program of innate immunity initiated by pathogens.
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The aptamer ARC1779 is a potent and specific inhibitor of von Willebrand Factor-mediated ex vivo platelet function in ST-elevation and non-STelevation acute myocardial infarction 
Materials and methods
Target-site penetration was evaluated in autopsy samples (lung, brain, kidneys, liver, spleen, heart) of two patients who had died during treatment with VOR. Patient 1 had obtained a single-dose of VOR (200 mg), the interval between the last administration and death was 36 hours. Patient 2 was on VOR therapy under steady-state (day 10, cumulative dose 3,800 mg). He died 12 hours after the last VOR infusion. Tissue samples were obtained during routine autopsy, homogenized, purified and quantified by HPLC.
Results
The VOR concentrations in patient 2 exceeded those measured in patient 1 in all tissue samples. The highest levels were determined in the liver (4.21 ± 0.77 g/L) and the kidneys (6.89 ± 0.06 g/L). Mean VOR lung concentration amounted to 1.30 ± 0.63 g/L (patient 1: 0.72 to 0.76 g/L; patient 2: 1.47 to 2.04 g/L). After a single administration VOR tissue levels in the brain were below the limit of detection (<0.25 g/L) and achieved concentrations of 3.34 ± 0.18 g/L under steady-state conditions. In the different areas of the brain (cortex, hippocampus, nucleus caudatus, medulla oblongata and cerebellum) similar VOR concentrations were found. VOR levels amounted to 1.31 ± 0.03 g/L and 2.95 ± 0.05 g/L in samples of the spleen of patient 1 and 2, respectively. In the myocardium samples of patient 1 VOR was not detectable, but reached a mean concentration of 2.44 ± 0.25 g/L in patient 2.
Conclusions
Even after a single administration, VOR could be detected in most tissues. Obviously, the drug accumulates in the organs of its elimination, the liver and the kidneys. The penetration into the brain and into the myocardium is probably slower.
The maximum lung concentrations appear to be below the levels achieved in other tissues. However, the levels may exceed the minimal inhibitory concentrations of most relevant fungal pathogens. 
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Materials and methods
Concentrations of the three therapeutically used lipid formulations were determined in human body fluids and compared to previous data from tissue samples and epithelial lining fluid. AmB levels in pleural effusion of seven patients, ascites of three patients and bile fluid obtained from one patient were analysed after administration of a lipid formulation. In order to calculate the penetration ratio the concentrations in pleural effusion and bile fluid were compared with simultaneous levels of lipid formulated AmB in plasma. All samples were purified by solid phase extraction and AmB was quantified by HPLC. 
Results
Conclusions
After treatment with lipid formulations, AmB concentrations in pleural effusion and in ascites were substantially lower in body fluids than in plasma samples and human tissue. Longterm treatment with high doses of AmB lipid formulations as well as additional therapeutic interventions will be required for the eradication of fungal pathogens from body fluids.
